FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973072791> ?p ?o ?g. }

• W2973072791 endingPage "7446" @default.
• W2973072791 startingPage "7431" @default.
• W2973072791 abstract "Low density lipoprotein (LDL) has been regarded as a promising antitumor drug vehicle. However some problems, such as rare source, difficulty of large-scale production, and potential safety concerns, hinder its clinical application.The objective of this study is to develop a biomimetic LDL nanocarrier by replacing the native apolipoprotein B-100 (apoB-100) with an artificial amphipathic peptide and demonstrate its antitumor efficacy.The amphipathic hybrid peptide (termed as FPL) consisting of a lipid binding motif of apoB-100 (LBMapoB)-polyethylene glycol (PEG)-folic acid (FA) was synthesized and characterized by 1H NMR and circular dichroism. FPL decorated lipoprotein-mimic nanoparticles (termed as FPLM NPs) were prepared by a modified solvent emulsification method. Paclitaxel (PTX) was incorporated into NPs and its content was quantified by HPLC analysis. The morphology of NPs was observed by transmission electron microscopy (TEM), and the particle size and zeta potential of NPs were determined by dynamic light scattering (DLS). The colloidal stability of FPLM NPs was evaluated in PBS containing bovine serum albumin (BSA). In vitro release of PTX loaded FPLM NPs was evaluated using the dialysis method. Cellular uptake and cytotoxity assayswere evaluated on human cervical cancer cells (HeLa) and lung cancer cells (A549). Tumor inhibition in vivo was investigated in M109 tumor-bearing mice via tail vein injection of Taxol formulation and PTX loaded NPs.The composition of FPLM NPs, including cholesteryl oleate, glyceryl trioleate, cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and FPL peptides, was optimized to be 5:1:1:3:10 (w/w). FPLM NPs had a spherical shape with a mean diameter of 83 nm and a negative charge (-12 mV). FPLM NPs with optimum formulation had good colloidal stability in BSA solution.The release of PTX from FPLM NPs was slow and sustained. The uptake of FPLM NPs was higher in folate receptor (FR) overexpressing tumor cells (HeLa cells) than in FR deficient tumor cells (A549 cells). The intracellular distribution indicated that FPLM NPs had the lysosome escape capacity. The internalization mechanism of FPLM NPs was involved with clathrin- and caveolae-mediated endocytosis and FR played a positive role in the internalization of FPLM NPs. The CCK-8 assay demonstrated that FPLM NPs exhibited notably better anti-tumor effect than Taxol formulation in vitro. Moreover, PTX loaded FPLM NPs produced very marked anti-tumor efficiency in M109 tumor-bearing mice in vivo.FPLM NPs is a promising nanocarrier which can improve the therapeutic effect and reduce the side effects of antitumor drugs." @default.
• W2973072791 created "2019-09-19" @default.
• W2973072791 creator A5004573511 @default.
• W2973072791 creator A5011611155 @default.
• W2973072791 creator A5017149483 @default.
• W2973072791 creator A5024020692 @default.
• W2973072791 creator A5043086908 @default.
• W2973072791 creator A5062813237 @default.
• W2973072791 creator A5077865481 @default.
• W2973072791 date "2019-09-01" @default.
• W2973072791 modified "2023-10-15" @default.
• W2973072791 title "<p>Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel</p>" @default.
• W2973072791 cites W1441169201 @default.
• W2973072791 cites W1571618989 @default.
• W2973072791 cites W1654802422 @default.
• W2973072791 cites W1963977788 @default.
• W2973072791 cites W1980485904 @default.
• W2973072791 cites W1985514851 @default.
• W2973072791 cites W2037578679 @default.
• W2973072791 cites W2049556830 @default.
• W2973072791 cites W2053728995 @default.
• W2973072791 cites W2056462125 @default.
• W2973072791 cites W2059503044 @default.
• W2973072791 cites W2062228103 @default.
• W2973072791 cites W2066423421 @default.
• W2973072791 cites W2085602936 @default.
• W2973072791 cites W2092682849 @default.
• W2973072791 cites W2092770422 @default.
• W2973072791 cites W2095142763 @default.
• W2973072791 cites W2095393642 @default.
• W2973072791 cites W2104993716 @default.
• W2973072791 cites W2111731115 @default.
• W2973072791 cites W2125123295 @default.
• W2973072791 cites W2130226375 @default.
• W2973072791 cites W2138841151 @default.
• W2973072791 cites W2144017583 @default.
• W2973072791 cites W2147584970 @default.
• W2973072791 cites W2207570231 @default.
• W2973072791 cites W2318531023 @default.
• W2973072791 cites W2546751650 @default.
• W2973072791 cites W2730071659 @default.
• W2973072791 cites W2952425633 @default.
• W2973072791 cites W2964963203 @default.
• W2973072791 cites W77345513 @default.
• W2973072791 doi "https://doi.org/10.2147/ijn.s215080" @default.
• W2973072791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6751769" @default.
• W2973072791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31686815" @default.
• W2973072791 hasPublicationYear "2019" @default.
• W2973072791 type Work @default.
• W2973072791 sameAs 2973072791 @default.
• W2973072791 citedByCount "8" @default.
• W2973072791 countsByYear W29730727912020 @default.
• W2973072791 countsByYear W29730727912021 @default.
• W2973072791 countsByYear W29730727912022 @default.
• W2973072791 countsByYear W29730727912023 @default.
• W2973072791 crossrefType "journal-article" @default.
• W2973072791 hasAuthorship W2973072791A5004573511 @default.
• W2973072791 hasAuthorship W2973072791A5011611155 @default.
• W2973072791 hasAuthorship W2973072791A5017149483 @default.
• W2973072791 hasAuthorship W2973072791A5024020692 @default.
• W2973072791 hasAuthorship W2973072791A5043086908 @default.
• W2973072791 hasAuthorship W2973072791A5062813237 @default.
• W2973072791 hasAuthorship W2973072791A5077865481 @default.
• W2973072791 hasBestOaLocation W29730727911 @default.
• W2973072791 hasConcept C121608353 @default.
• W2973072791 hasConcept C12554922 @default.
• W2973072791 hasConcept C126322002 @default.
• W2973072791 hasConcept C13245373 @default.
• W2973072791 hasConcept C14631669 @default.
• W2973072791 hasConcept C150903083 @default.
• W2973072791 hasConcept C155672457 @default.
• W2973072791 hasConcept C15920480 @default.
• W2973072791 hasConcept C171250308 @default.
• W2973072791 hasConcept C178790620 @default.
• W2973072791 hasConcept C18150654 @default.
• W2973072791 hasConcept C185592680 @default.
• W2973072791 hasConcept C192562407 @default.
• W2973072791 hasConcept C202751555 @default.
• W2973072791 hasConcept C204399865 @default.
• W2973072791 hasConcept C207001950 @default.
• W2973072791 hasConcept C2776964284 @default.
• W2973072791 hasConcept C2777292972 @default.
• W2973072791 hasConcept C2777366897 @default.
• W2973072791 hasConcept C2779820397 @default.
• W2973072791 hasConcept C521977710 @default.
• W2973072791 hasConcept C55493867 @default.
• W2973072791 hasConcept C67407626 @default.
• W2973072791 hasConcept C71924100 @default.
• W2973072791 hasConcept C86181022 @default.
• W2973072791 hasConcept C86803240 @default.
• W2973072791 hasConceptScore W2973072791C121608353 @default.
• W2973072791 hasConceptScore W2973072791C12554922 @default.
• W2973072791 hasConceptScore W2973072791C126322002 @default.
• W2973072791 hasConceptScore W2973072791C13245373 @default.
• W2973072791 hasConceptScore W2973072791C14631669 @default.
• W2973072791 hasConceptScore W2973072791C150903083 @default.
• W2973072791 hasConceptScore W2973072791C155672457 @default.
• W2973072791 hasConceptScore W2973072791C15920480 @default.

• next